MA25265A1 - Antagoniste du recepteur de vitronectime. - Google Patents

Antagoniste du recepteur de vitronectime.

Info

Publication number: MA25265A1
Authority: MA; Morocco
Prior art keywords: vitronectime; receptor antagonist; antagonist; receptor; vitronectime receptor
Prior art date: 1998-12-04

Application number

MA26218A

Other languages

English (en)

Inventor

J Manley Peter

H Miller William

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-04

Filing date

2001-06-01

Publication date

2001-10-01

2001-06-01 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2001-10-01 Publication of MA25265A1 publication Critical patent/MA25265A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

MA26218A 1998-12-04 2001-06-01 Antagoniste du recepteur de vitronectime. MA25265A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11090398P	1998-12-04	1998-12-04

Publications (1)

Publication Number	Publication Date
MA25265A1 true MA25265A1 (fr)	2001-10-01

Family

ID=22335565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26218A MA25265A1 (fr)	1998-12-04	2001-06-01	Antagoniste du recepteur de vitronectime.

Country Status (39)

Country	Link
US (1)	US6495560B1 (fr)
EP (1)	EP1146874B1 (fr)
JP (1)	JP4481504B2 (fr)
KR (1)	KR100620485B1 (fr)
CN (1)	CN1147300C (fr)
AP (1)	AP1534A (fr)
AR (1)	AR035006A1 (fr)
AT (1)	ATE277043T1 (fr)
AU (1)	AU754408B2 (fr)
BG (1)	BG65118B1 (fr)
BR (1)	BR9915879A (fr)
CA (1)	CA2353415A1 (fr)
CO (1)	CO5150166A1 (fr)
CZ (1)	CZ20011963A3 (fr)
DE (1)	DE69920518T2 (fr)
DK (1)	DK1146874T3 (fr)
DZ (1)	DZ2954A1 (fr)
EA (1)	EA003254B1 (fr)
EG (1)	EG24025A (fr)
ES (1)	ES2229798T3 (fr)
HK (1)	HK1042037B (fr)
HU (1)	HUP0104804A3 (fr)
ID (1)	ID28811A (fr)
IL (2)	IL143390A0 (fr)
MA (1)	MA25265A1 (fr)
NO (1)	NO318895B1 (fr)
NZ (1)	NZ511876A (fr)
OA (1)	OA11724A (fr)
PE (1)	PE20001563A1 (fr)
PL (1)	PL195973B1 (fr)
PT (1)	PT1146874E (fr)
SI (1)	SI1146874T1 (fr)
SK (1)	SK7452001A3 (fr)
TR (1)	TR200101654T2 (fr)
TW (1)	TW482673B (fr)
UA (1)	UA71586C2 (fr)
UY (1)	UY25824A1 (fr)
WO (1)	WO2000033838A1 (fr)
ZA (1)	ZA200104398B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6900232B2 (en)	2000-06-15	2005-05-31	Pharmacia Corporation	Cycloalkyl alkanoic acids as integrin receptor antagonists
AU2002239435B2 (en) *	2000-10-24	2005-10-27	Merck & Co., Inc.	Dibenzoxazepine alpha v integrin receptor antagonist
JP4615826B2 (ja)	2001-01-29	2011-01-19	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US6872730B2 (en) *	2001-04-27	2005-03-29	3-Dimensional Pharmaceuticals, Inc.	Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en)	2002-08-16	2004-11-11	Bart De Corte	Piperidinyl targeting compounds that selectively bind integrins
MXPA05006587A (es)	2002-12-20	2005-12-14	Pharmacia Corp	Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
GB0319069D0 (en) *	2003-08-14	2003-09-17	Glaxo Group Ltd	Therapeutically useful compounds
EP1841406A4 (fr) *	2004-12-21	2008-06-25	Smithkline Beecham Corp	Procedes et formulations
PL2593452T3 (pl)	2010-07-14	2017-07-31	Novartis Ag	Związki heterocykliczne będące agonistami receptora IP
TW201335160A (zh)	2012-01-13	2013-09-01	Novartis Ag	Ｉｐ受體激動劑之雜環化合物
US9604981B2 (en)	2013-02-13	2017-03-28	Novartis Ag	IP receptor agonist heterocyclic compounds
HUE063437T2 (hu)	2013-09-24	2024-01-28	Fujifilm Corp	Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2687154B1 (fr) *	1992-02-07	1995-05-12	Rhone Poulenc Rorer Sa	Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
WO1997001540A1 (fr)	1995-06-29	1997-01-16	Smithkline Beecham Corporation	Antagonistes du recepteur de l'integrine
WO1998013278A1 (fr) *	1996-09-27	1998-04-02	Merkler, H.	Cuve pour liquides, en particulier pour liquides chimiquement corrosifs
EP0946180A4 (fr)	1996-10-07	2003-07-23	Smithkline Beecham Corp	Procede de stimulation de la formation osseuse
UY24949A1 (es)	1997-04-08	2001-04-30	Smithkline Beecham Corp	Compuestos calcilíticos

1999
- 1999-03-12 UA UA2001063754A patent/UA71586C2/uk unknown
- 1999-11-29 UY UY25824A patent/UY25824A1/es unknown
- 1999-11-29 TW TW088120752A patent/TW482673B/zh not_active IP Right Cessation
- 1999-11-30 PE PE1999001197A patent/PE20001563A1/es not_active Application Discontinuation
- 1999-11-30 CO CO99075061A patent/CO5150166A1/es unknown
- 1999-12-01 DZ DZ990254A patent/DZ2954A1/fr active
- 1999-12-02 EG EG154299A patent/EG24025A/xx active
- 1999-12-02 AR ARP990106128A patent/AR035006A1/es unknown
- 1999-12-03 DE DE69920518T patent/DE69920518T2/de not_active Expired - Lifetime
- 1999-12-03 OA OA1200100139A patent/OA11724A/en unknown
- 1999-12-03 US US09/857,316 patent/US6495560B1/en not_active Expired - Lifetime
- 1999-12-03 PT PT99960647T patent/PT1146874E/pt unknown
- 1999-12-03 WO PCT/US1999/028662 patent/WO2000033838A1/fr not_active Ceased
- 1999-12-03 BR BR9915879-5A patent/BR9915879A/pt not_active Application Discontinuation
- 1999-12-03 CZ CZ20011963A patent/CZ20011963A3/cs unknown
- 1999-12-03 DK DK99960647T patent/DK1146874T3/da active
- 1999-12-03 CA CA002353415A patent/CA2353415A1/fr not_active Abandoned
- 1999-12-03 ES ES99960647T patent/ES2229798T3/es not_active Expired - Lifetime
- 1999-12-03 JP JP2000586330A patent/JP4481504B2/ja not_active Expired - Fee Related
- 1999-12-03 AP APAP/P/2001/002156A patent/AP1534A/en active
- 1999-12-03 ID IDW00200101183A patent/ID28811A/id unknown
- 1999-12-03 TR TR2001/01654T patent/TR200101654T2/xx unknown
- 1999-12-03 SI SI9930700T patent/SI1146874T1/xx unknown
- 1999-12-03 KR KR1020017006937A patent/KR100620485B1/ko not_active Expired - Fee Related
- 1999-12-03 HU HU0104804A patent/HUP0104804A3/hu unknown
- 1999-12-03 EA EA200100618A patent/EA003254B1/ru not_active IP Right Cessation
- 1999-12-03 PL PL99348702A patent/PL195973B1/pl not_active IP Right Cessation
- 1999-12-03 SK SK745-2001A patent/SK7452001A3/sk unknown
- 1999-12-03 AT AT99960647T patent/ATE277043T1/de not_active IP Right Cessation
- 1999-12-03 EP EP99960647A patent/EP1146874B1/fr not_active Expired - Lifetime
- 1999-12-03 IL IL14339099A patent/IL143390A0/xx active IP Right Grant
- 1999-12-03 CN CNB998159735A patent/CN1147300C/zh not_active Expired - Fee Related
- 1999-12-03 NZ NZ511876A patent/NZ511876A/xx unknown
- 1999-12-03 HK HK02101522.3A patent/HK1042037B/en not_active IP Right Cessation
- 1999-12-03 AU AU17502/00A patent/AU754408B2/en not_active Ceased
2001
- 2001-05-24 IL IL143390A patent/IL143390A/en not_active IP Right Cessation
- 2001-05-29 ZA ZA200104398A patent/ZA200104398B/en unknown
- 2001-06-01 MA MA26218A patent/MA25265A1/fr unknown
- 2001-06-01 NO NO20012732A patent/NO318895B1/no not_active IP Right Cessation
- 2001-06-26 BG BG105651A patent/BG65118B1/bg unknown

Also Published As

Publication number	Publication date
BG105651A (en)	2002-02-28
DZ2954A1 (fr)	2004-06-20
CO5150166A1 (es)	2002-04-29
PT1146874E (pt)	2005-02-28
EA200100618A1 (ru)	2001-12-24
JP2003523931A (ja)	2003-08-12
BG65118B1 (bg)	2007-03-30
NO20012732L (no)	2001-08-01
PE20001563A1 (es)	2001-02-09
NO20012732D0 (no)	2001-06-01
HK1042037A1 (en)	2002-08-02
BR9915879A (pt)	2002-02-13
UY25824A1 (es)	2001-07-31
US6495560B1 (en)	2002-12-17
EP1146874B1 (fr)	2004-09-22
ID28811A (id)	2001-07-05
IL143390A0 (en)	2002-04-21
EP1146874A1 (fr)	2001-10-24
TW482673B (en)	2002-04-11
ES2229798T3 (es)	2005-04-16
IL143390A (en)	2006-07-05
EA003254B1 (ru)	2003-02-27
AP1534A (en)	2006-01-09
DK1146874T3 (da)	2005-01-31
DE69920518T2 (de)	2005-09-22
ZA200104398B (en)	2002-05-29
AU754408B2 (en)	2002-11-14
AR035006A1 (es)	2004-04-14
OA11724A (en)	2005-01-26
SK7452001A3 (en)	2001-12-03
KR20010080669A (ko)	2001-08-22
HUP0104804A3 (en)	2002-12-28
NO318895B1 (no)	2005-05-18
EG24025A (en)	2008-03-26
JP4481504B2 (ja)	2010-06-16
CZ20011963A3 (cs)	2001-11-14
KR100620485B1 (ko)	2006-09-13
UA71586C2 (en)	2004-12-15
EP1146874A4 (fr)	2002-06-05
PL195973B1 (pl)	2007-11-30
PL348702A1 (en)	2002-06-03
SI1146874T1 (en)	2005-04-30
ATE277043T1 (de)	2004-10-15
WO2000033838A1 (fr)	2000-06-15
CN1147300C (zh)	2004-04-28
NZ511876A (en)	2004-02-27
DE69920518D1 (de)	2004-10-28
TR200101654T2 (tr)	2002-03-21
HK1042037B (en)	2005-07-29
CA2353415A1 (fr)	2000-06-15
AU1750200A (en)	2000-06-26
CN1334730A (zh)	2002-02-06
HUP0104804A2 (hu)	2002-05-29

Publication	Publication Date	Title
MA25403A1 (fr)	2002-04-01	Ligandes de recepteur de melanocortine
ATE280157T1 (de)	2004-11-15	4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
MA26762A1 (fr)	2004-12-20	Derives de pyrrolidine- antagonistes du recepteur ccr-3
NO20012948D0 (no)	2001-06-14	Hydroksydifenylureasulfonamider som IL-8 reseptor antagonister
IS5706A (is)	2000-11-07	Adenosín A3 viðtakastillar
CY2010003I2 (el)	2012-01-25	Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE60026169D1 (de)	2006-04-27	Selektive neurokinin-antagonisten
BR9712248A (pt)	1999-08-24	Antagonista receptores de vitronectina
EP0880511A4 (fr)	1999-06-16	Antagonistes du recepteur integrine
DE69919171D1 (de)	2004-09-09	Muskarin-rezeptor antagonisten
NO20004503D0 (no)	2000-09-08	Vitronectin-reseptor-antagonister
NO20016053D0 (no)	2001-12-11	IL-8 reseptor-antagonister
ATE286022T1 (de)	2005-01-15	Naphthalin-carboxamide als tachykinin rezeptorantagonisten
MA25265A1 (fr)	2001-10-01	Antagoniste du recepteur de vitronectime.
NO20016052L (no)	2001-12-11	IL-8-reseptor-antagonister
ATE352299T1 (de)	2007-02-15	Il-8 rezeptorantagonist
EP1003333A4 (fr)	2004-03-17	Recepteur
EP1239033A4 (fr)	2004-11-24	Recepteur de semaphorine
EP0912182A4 (fr)	1999-12-29	Promedicaments antagonistes du recepteur de fibrinogene
NO20015774D0 (no)	2001-11-27	IL-8 reseptorantagonister
EP1023295A4 (fr)	2001-01-24	Promedicaments antagonistes de recepteur de fibrinogene
NO20010620D0 (no)	2001-02-06	Vitronektinreseptor-antagonister
NO20010353L (no)	2001-01-22	IL-8 reseptor-antagonist
EP0781133A4 (fr)	1997-12-10	Antagonistes du recepteur de fibrinogene
EP1006667A4 (fr)	2003-04-16	Recepteur